article thumbnail

Navigating the challenges of cell therapies

Drug Target Review

Problem w/ CTs and foundational understanding of Vittoria: can you explore the current limitations of cell therapies and the challenges faced by patients and providers? Currently, only a small percentage of cancers can be effectively treated with cell therapies, and there is little diversity in the currently approved products.

Therapies 116
article thumbnail

Six scientists named as new core institute members at Broad

Broad Institute

At the Broad, he directs the Cancer Genome Computational Analysis Group , and he is a professor of pathology at Harvard Medical School and director of bioinformatics at Massachusetts General Hospital. He is also an associate professor of psychiatry at Massachusetts General Hospital and Harvard Medical School.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Researchers identify source of a brain cancer’s deadly transformation

Broad Institute

Bernstein is also chair of the Department of Cancer Biology at Dana-Farber Cancer Institute, a professor in cell biology and pathology at Harvard Medical School, and holds the Richard and Nancy Lubin Family Chair. Improving therapy Moreover, the researchers discovered a new effect of the excessive methylation.

Research 124
article thumbnail

#ScienceSaturday: April 6, 2024

KIF1A

Read the Article Rare Roundup Columbia Receives $15M for Ultra-Rare ALS Medicines Creation Gene-based therapies like Antisense Oligonucleotides have taken major strides in recent years, including Susannah Rosen’s current n-of-1 ASO trial. She graduated from UC San Diego with a B.S. degree in human biology in 2023.

DNA 111
article thumbnail

Advancing CAR-T therapy: how CD5 modulation is shaping cancer treatment

Drug Target Review

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

article thumbnail

Drug Target Review – Issue 3 2023

Drug Target Review

Dr Cristina Ureche from Hannover Medical School (MHH) guides us through the aseptic process of viral vector-based vaccines, and Dr Mark J. Dr Brian Kaspar of Insmed Incorporated guides us from bench to bedside, addressing key challenges in gene therapy. Newman of GeoVax, Inc.,

Vaccine 106
article thumbnail

Revolutionary nanoparticles enable gene-editing in lungs

Drug Target Review

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs. The study appears in Nature Biotechnology.

RNA 98